Prodrugs in Oncology: Bioactivation and Impact on Therapeutic Efficacy and Toxicity
International Journal of Molecular Sciences · 24.01.2025 · 26 (3) · 988
DOI: 10.3390/ijms26030988 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 24.01.2025. Verfasst von Ritika Kurian und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Sciences, University of Maryland School of Pharmacy, 20 Penn Street, Baltimore, MD 21201, USA. Hauptthemen laut MEDLINE: Prodrugs, Neoplasms, Antineoplastic Agents. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 229 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, FDA HHS, National Institutes of Health National Cancer Institute.
Abstract (Originalsprache)
A prodrug is a molecule that lacks pharmacological activity, but upon enzymatic bioactivation, it can generate a therapeutically active molecule. The primary reason behind the design of a prodrug is to help circumvent challenges associated with the physicochemical properties of a drug molecule, such as solubility, absorption, distribution, and instability. Chemotherapy has been at the forefront of cancer treatment for over 70 years due to its ability to target rapidly proliferating tumor cells. However, a major concern with conventional chemotherapy is the lack of selectivity and its associated side toxicity, which can severely impact patients’ quality of life. In oncology, prodrugs have been explored to enhance the bioavailability, improve efficacy, and minimize systemic toxicity of chemotherapeutic agents. Prodrugs activated by enzymes unique to a tumor microenvironment can significantly increase targeted delivery of chemotherapeutic drugs. This review aims to highlight commonly used chemotherapeutic prodrugs, including both alkylating and non-alkylating agents, and discuss their clinical relevance, mechanisms of bioactivation, and toxicity concerns.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutical Sciences, University of Maryland School of Pharmacy, 20 Penn Street, Baltimore, MD 21201, USA.
ORCID-Profile: Hongbing Wang
Förderung
- NCI NIH HHS
- FDA HHS
- National Institutes of Health National Cancer Institute
- Food and Drug Administration (FDA) of the U.S.
Zitieren
APA
Kurian, R., & Wang, H. (2025). Prodrugs in Oncology: Bioactivation and Impact on Therapeutic Efficacy and Toxicity. International Journal of Molecular Sciences, 26(3), 988. https://doi.org/10.3390/ijms26030988
Vancouver
Kurian R, Wang H. Prodrugs in Oncology: Bioactivation and Impact on Therapeutic Efficacy and Toxicity. International Journal of Molecular Sciences. 2025;26(3):988. doi:10.3390/ijms26030988
BibTeX
@article{Kurian2025,
author = {Kurian, Ritika and Wang, Hongbing},
title = {Prodrugs in Oncology: Bioactivation and Impact on Therapeutic Efficacy and Toxicity},
journal = {International Journal of Molecular Sciences},
year = {2025},
volume = {26},
number = {3},
pages = {988},
doi = {10.3390/ijms26030988}
}
EUVIMED